75 related articles for article (PubMed ID: 25408210)
1. Understanding the beneficial and detrimental effects of donepezil and rivastigmine to improve their therapeutic value.
Lane RM; Darreh-Shori T
J Alzheimers Dis; 2015; 44(4):1039-62. PubMed ID: 25408210
[TBL] [Abstract][Full Text] [Related]
2. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice.
Furukawa-Hibi Y; Alkam T; Nitta A; Matsuyama A; Mizoguchi H; Suzuki K; Moussaoui S; Yu QS; Greig NH; Nagai T; Yamada K
Behav Brain Res; 2011 Nov; 225(1):222-9. PubMed ID: 21820013
[TBL] [Abstract][Full Text] [Related]
3. Donepezil can improve daily activities and promote rehabilitation for severe Alzheimer's patients in long-term care health facilities.
Meguro K; Ouchi Y; Akanuma K; Meguro M; Kasai M
BMC Neurol; 2014 Dec; 14():243. PubMed ID: 25516360
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease.
Shao ZQ
Int J Clin Exp Med; 2015; 8(2):2944-8. PubMed ID: 25932260
[TBL] [Abstract][Full Text] [Related]
5. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow changes in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial.
Shimizu S; Kanetaka H; Hirose D; Sakurai H; Hanyu H
Dement Geriatr Cogn Dis Extra; 2015; 5(1):135-46. PubMed ID: 25999980
[TBL] [Abstract][Full Text] [Related]
7. Combination Therapy of Cholinesterase Inhibitor (Donepezil or Galantamine) plus Memantine in the Okayama Memantine Study.
Matsuzono K; Hishikawa N; Ohta Y; Yamashita T; Deguchi K; Nakano Y; Abe K
J Alzheimers Dis; 2015; 45(3):771-80. PubMed ID: 25624417
[TBL] [Abstract][Full Text] [Related]
8. Multimodality imaging of Alzheimer disease and other neurodegenerative dementias.
Nasrallah IM; Wolk DA
J Nucl Med; 2014 Dec; 55(12):2003-11. PubMed ID: 25413136
[TBL] [Abstract][Full Text] [Related]
9. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
Deardorff WJ; Feen E; Grossberg GT
Drugs Aging; 2015 Jul; 32(7):537-47. PubMed ID: 26033268
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
Farlow MR; Sadowsky CH; Velting DM; Meng X; Islam MZ
CNS Neurosci Ther; 2015 Jun; 21(6):513-9. PubMed ID: 25675992
[TBL] [Abstract][Full Text] [Related]
11. Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Bono GF; Simão-Silva DP; Batistela MS; Josviak ND; Dias PF; Nascimento GA; Souza RL; Piovezan MR; Souza RK; Furtado-Alle L
Neurochem Int; 2015 Feb; 81():57-62. PubMed ID: 25624079
[TBL] [Abstract][Full Text] [Related]
12. A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease.
Farlow MR; Grossberg GT; Sadowsky CH; Meng X; Velting DM
Alzheimer Dis Assoc Disord; 2015; 29(2):110-6. PubMed ID: 25437301
[TBL] [Abstract][Full Text] [Related]
13. Cognitive disorders in diabetic patients.
Koekkoek PS; Rutten GE; Biessels GJ
Handb Clin Neurol; 2014; 126():145-66. PubMed ID: 25410220
[TBL] [Abstract][Full Text] [Related]
14. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis.
Atri A; Hendrix SB; Pejović V; Hofbauer RK; Edwards J; Molinuevo JL; Graham SM
Alzheimers Res Ther; 2015; 7(1):28. PubMed ID: 25991927
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.
Hogan DB
Can J Psychiatry; 2014 Dec; 59(12):618-23. PubMed ID: 25702360
[TBL] [Abstract][Full Text] [Related]
16. Additional donepezil treatment for patients with geriatric depression who exhibit cognitive deficit during treatment for depression.
Inoue J; Hoshino R; Nojima H; Ishida W; Okamoto N
Psychogeriatrics; 2016 Jan; 16(1):54-61. PubMed ID: 25919986
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's disease and Parkinson's disease dementia.
Sadowsky CH; Micca JL; Grossberg GT; Velting DM
Prim Care Companion CNS Disord; 2014; 16(5):. PubMed ID: 25667813
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of clinical response to cholinesterase inhibitors in mild and moderate Alzheimer's disease and mixed dementia: a one-year naturalistic study.
Miranda LF; Gomes KB; Silveira JN; Pianetti GA; Byrro RM; Peles PR; Pereira FH; Santos TR; Assini AG; Ribeiro VV; Tito PA; Matoso RO; Lima TO; Moraes EN; Caramelli P
J Alzheimers Dis; 2015; 45(2):609-20. PubMed ID: 25589728
[TBL] [Abstract][Full Text] [Related]
19. Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Grossberg GT; Farlow MR; Meng X; Velting DM
Curr Alzheimer Res; 2015; 12(1):53-60. PubMed ID: 25523430
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
